BET+ is bringing back The Ms. Pat Show in January, officially confirming a fifth season and unveiling a teaser that signals another bold chapter for the Emmy-nominated comedy. The series stars ...

Jonathan Capehart will interview Obama in Los Angeles about her new book 'The Look,' with the special airing Dec. 18. By Alex Weprin Senior Editor Former First Lady Michelle Obama is set for a rare ...

The streaming wars have a new entrant. Versant, the cable-heavy company slated to be spun off early next year from NBCUniversal, plans to introduce a new streaming outlet tied to MS NOW in the middle ...

The new direct-to-consumer offering from MS NOW is being pitched as different from other subscription digital offerings, but it will include 24/7 access to the linear network. Announced at the Versant ...

The service will be "centered around community, membership, and democracy and as a digital hub for progressives," parent company Versant says. By Alex Weprin Senior Editor Fear not, MS NOW super-fans: ...

MSNBC officially rebranded to MS NOW, which stands for My Source for News, Opinion and the World, on Saturday. The name change, which was announced in August, comes as the cable network moves to a new ...

Morning Joe cohosts Joe Scarborough and Mika Brzezinski shared their thoughts on MSNBC’s rebrand to MS Now. Both hosts highlighted the show’s adaptability over nearly 20 years, noting their excitement ...

MS NOW sheds the last of its old MSNBC identity. MS NOW sheds the last of its old MSNBC identity. is a news writer covering all things consumer tech. Stevie started out at Laptop Mag writing news ...

It's a new dawn for MSNBC, which is being rebranded and will now be known as MS NOW. The transition comes as the channel breaks off from its current parent company, Comcast NBCUniversal, and moves to ...

Saturday will mark the end of an era for MSNBC as the liberal cable network moves forward under new ownership and a new name: MS NOW. The media shakeup was nearly a year in the making after Comcast ...

Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...